^
    Back
    Association details:
    Biomarker:EGFR T790M
    Cancer:Non Small Cell Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor) +
    navitoclax (ABT 263) (Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

    Excerpt:
    ...- Adequate archival tissue from a biopsy performed after progression of disease on previous EGFR TKI; or willing to undergo a new tumor biopsy prior to registration (for the dose escalation portion only this requirement can be waived if T790M status has already been determined using a local assay)...
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903)

    Published date:
    12/29/2020
    Excerpt:
    This single arm phase IB study evaluated safety, tolerability and feasibility of osimertinib and navitoclax, including dose expansion in T790M+ patients at the recommended phase 2 dose (RP2D)….In expansion cohort, objective response rate (ORR) was 100% and median progression-free survival (PFS) was 16.8 months.
    DOI:
    10.1158/1078-0432.CCR-20-4084